Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...
Drug development in biotechnology takes time. A lot of time. On average, it takes 10 to 15 years to take a medicine from ...
After three decades spent rising through the ranks of sales and marketing teams at major pharmas, Chris Boulton is taking the ...
Generalized myasthenia gravis is Uplizna’s second new indication this year, after the FDA cleared the anti-CD19 antibody for ...
Amgen (AMGN) “announced that the FDA has approved UPLIZNA, inebilizumab-cdon, for the treatment of generalized myasthenia ...
Amgen (AMGN) announced that the FDA has approved Uplinza, inebilizumab-cdon, for the treatment of generalized myasthenia ...
The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA ® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...
Curious if Amgen is worth your investment dollars right now? Let’s take a clear-eyed look at where the stock stands and whether the value justifies the price. Amgen's stock has been on a strong upward ...
Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...
FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies
The FDA’s approval of Uplizna for antibody-positive generalized myasthenia gravis introduces a twice-yearly CD19-targeted therapy option for the rare autoimmune condition. The FDA has approved Amgen’s ...
Amgen’s stock narrative is shifting, as reflected in a slight but noticeable increase in the consensus analyst price target ...
Amgen secures FDA approval for Uplinza in generalized myasthenia gravis, giving antibody-positive adults a targeted treatment option supported by Phase 3 data.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback